ArticleCancer medicine2025
Reimbursement of Lung Cancer in Turkey: A 10-Year Single Center Study.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Impact of NAD(P)H: Quinone Oxidoreductase 1 (NQO1) C609T Polymorphism on Lung Cancer Risk.Medicina (Kaunas, Lithuania) · 2025Article
- Reimbursement of Lung Cancer in Turkey: A 10-Year Single Center Study.Cancer medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
OBJECTIVE AND
backgroundLung cancer is the most common carcinoma reported worldwide. The burden of lung carcinoma on healthcare has been reported in many countries, while a real-life report within Turkey has yet to be published. This study aims to present the available results from a tertiary center specializing in pulmonology.
methodsThe study's population consisted of 199.112 patient admissions, which were reimbursed under the national healthcare system. After exclusion criteria, 4.991 patients were evaluated in the study. The patient's demographic data, malignancy types, diagnostic methods for lung carcinoma type and staging, and treatment modalities were recorded.
resultsThe average healthcare expenditure during the treatment duration was 4289.4 (± 3739.4) USD, and the median was 3219.9 USD. The average expenditure was higher for male patients (3260 to 2977 USD, p = 0.003). Survivors had an overall lower healthcare expenditure than the non-survivor group (2865 to 4230 USD). Patients with locally advanced disease classification also had a higher expenditure on other stages (p < 0.001). This was not present in SCLC, as those diagnosed with SCLC had the most expenditure at the limited stage (p < 0.001). Carcinoid tumors had the least expenditure compared to other subtypes at limited and advanced stages (p < 0.001). SCLC had the highest expenditure requirement at the limited stage (p < 0.001). At the locally advanced stage, large cell carcinoma, SCC, and adenocarcinoma were the subtypes requiring the highest expenditure (p < 0.001).
conclusionThe parameters affecting overall cost were age, gender, stage, and malignancy subtype. The healthcare expenditure was also affected by the difficulty of diagnosis, with the non-diagnostic patient group having an overall higher cost. A longer duration of hospitalization and treatment given on an inpatient basis also contributed to a higher cost of care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.